BR0007394A - Método de usar quinoxalinas de(2-imidazolin-2-ilamino) no tratamento de lesãonervosa - Google Patents
Método de usar quinoxalinas de(2-imidazolin-2-ilamino) no tratamento de lesãonervosaInfo
- Publication number
- BR0007394A BR0007394A BR0007394-6A BR0007394A BR0007394A BR 0007394 A BR0007394 A BR 0007394A BR 0007394 A BR0007394 A BR 0007394A BR 0007394 A BR0007394 A BR 0007394A
- Authority
- BR
- Brazil
- Prior art keywords
- imidazolin
- ylamino
- quinoxalines
- treatment
- hydrogen
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Ophthalmology & Optometry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Patente de Invenção: "MéTODO DE USAR QUINOXALINAS DE(2-IMIDAZOLIN-2-ILAMINO) NO TRATAMENTO DE LESãONERVOSA". A presente invenção refere-se a um método deproteger as células nervosas ópticas ou retinais de um mamíferoque compreende administrar ao dito mamífero que sofre ou emrisco de sofrer de uma ação nociva nas ditas células nervosas umaquantidade eficaz de um composto da fórmula I para inibir ou evitardano ou morte de célula nervosa em que o grupo2-imidazolin-2-ilamino está ou na posição 5 ou 6 dos núcleos dequinoxalina; x, y e z estão em qualquer uma das posições restantes5, 6, 7 ou 8 e são selecionados de hidrogênio, halogênio, alquilainferior, alcóxi inferior ou trifluorometila; e R é um substituinteopcional ou na posição 2 ou 3 dos núcleos de quinoxalina e podeser hidrogênio, alquila inferior ou alcóxi inferior, ou seus saisfarmaceuticamente aceitáveis e misturas destes. Tal ação nocivapode resultar de neuropatia óptica glaucomatosa; degeneraçãomacular relacionada com a idade ou retinite pigmentosa.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/225,036 US6194415B1 (en) | 1995-06-28 | 1999-01-04 | Method of using (2-imidazolin-2-ylamino) quinoxoalines in treating neural injury |
PCT/US2000/000068 WO2000040245A1 (en) | 1999-01-04 | 2000-01-04 | Method of using (2-imidazolin-2-ylamino) quinoxalines in treating neural injury |
Publications (1)
Publication Number | Publication Date |
---|---|
BR0007394A true BR0007394A (pt) | 2001-10-30 |
Family
ID=22843255
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR0007394-6A BR0007394A (pt) | 1999-01-04 | 2000-01-04 | Método de usar quinoxalinas de(2-imidazolin-2-ilamino) no tratamento de lesãonervosa |
Country Status (12)
Country | Link |
---|---|
US (6) | US6194415B1 (pt) |
EP (1) | EP1146877B1 (pt) |
JP (2) | JP2002534387A (pt) |
CN (1) | CN1205932C (pt) |
AT (1) | ATE311187T1 (pt) |
AU (1) | AU762641B2 (pt) |
BR (1) | BR0007394A (pt) |
CA (1) | CA2357014C (pt) |
DE (1) | DE60024407T2 (pt) |
ES (1) | ES2251968T3 (pt) |
HK (1) | HK1040938B (pt) |
WO (1) | WO2000040245A1 (pt) |
Families Citing this family (80)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5856329A (en) * | 1995-06-28 | 1999-01-05 | Allergan | Method of using (2-imidazolin-2-ylamino) quinoxalines in treating ocular neural injury |
US6294553B1 (en) | 2000-02-15 | 2001-09-25 | Allergan Sales, Inc. | Method for treating ocular pain |
US7708711B2 (en) | 2000-04-14 | 2010-05-04 | Glaukos Corporation | Ocular implant with therapeutic agents and methods thereof |
US7867186B2 (en) | 2002-04-08 | 2011-01-11 | Glaukos Corporation | Devices and methods for treatment of ocular disorders |
US6638239B1 (en) * | 2000-04-14 | 2003-10-28 | Glaukos Corporation | Apparatus and method for treating glaucoma |
US20040111050A1 (en) * | 2000-04-14 | 2004-06-10 | Gregory Smedley | Implantable ocular pump to reduce intraocular pressure |
US20020143284A1 (en) * | 2001-04-03 | 2002-10-03 | Hosheng Tu | Drug-releasing trabecular implant for glaucoma treatment |
AU2002248284A1 (en) * | 2000-11-01 | 2002-08-06 | Allergan, Inc. | Compositions for treatment of ocular neovascularization |
US20030082183A1 (en) * | 2000-11-01 | 2003-05-01 | Wheeler Larry A. | Methods and compositions for treatment of ocular neovascularization and neural injury |
AU2006201701B2 (en) * | 2000-11-01 | 2007-07-12 | Allergan, Inc. | Methods and compositions for treatment of ocular neovascularization and neural injury |
EP1977724A1 (en) * | 2001-04-07 | 2008-10-08 | Glaukos Corporation | System for treating ocular disorders |
US7431710B2 (en) | 2002-04-08 | 2008-10-07 | Glaukos Corporation | Ocular implants with anchors and methods thereof |
US7678065B2 (en) * | 2001-05-02 | 2010-03-16 | Glaukos Corporation | Implant with intraocular pressure sensor for glaucoma treatment |
US20020198209A1 (en) * | 2001-05-03 | 2002-12-26 | Allergan Sales Inc. | Compositions having enhanced pharmacokinetic characteristics |
AU2002305400A1 (en) | 2001-05-03 | 2002-11-18 | Glaukos Corporation | Medical device and methods of use for glaucoma treatment |
US6838074B2 (en) | 2001-08-08 | 2005-01-04 | Bristol-Myers Squibb Company | Simultaneous imaging of cardiac perfusion and a vitronectin receptor targeted imaging agent |
US7331984B2 (en) * | 2001-08-28 | 2008-02-19 | Glaukos Corporation | Glaucoma stent for treating glaucoma and methods of use |
US7163543B2 (en) * | 2001-11-08 | 2007-01-16 | Glaukos Corporation | Combined treatment for cataract and glaucoma treatment |
US6761694B2 (en) | 2001-12-13 | 2004-07-13 | Allergan, Inc. | Methods for measuring retinal damage |
WO2003061519A2 (en) * | 2002-01-18 | 2003-07-31 | Massachusetts Eye And Ear Infirmary | Methods and compositions for preserving the viability of photoreceptor cells |
US7951155B2 (en) | 2002-03-15 | 2011-05-31 | Glaukos Corporation | Combined treatment for cataract and glaucoma treatment |
US9301875B2 (en) | 2002-04-08 | 2016-04-05 | Glaukos Corporation | Ocular disorder treatment implants with multiple opening |
US7030149B2 (en) | 2002-04-19 | 2006-04-18 | Allergan, Inc. | Combination of brimonidine timolol for topical ophthalmic use |
US7642258B2 (en) * | 2002-04-19 | 2010-01-05 | Allergan, Inc. | Combination of brimonidine and timolol for topical ophthalmic use |
US20040266776A1 (en) * | 2003-06-25 | 2004-12-30 | Gil Daniel W. | Methods of preventing and reducing the severity of stress-associated conditions |
US7273889B2 (en) * | 2002-09-25 | 2007-09-25 | Innovative Drug Delivery Systems, Inc. | NMDA receptor antagonist formulation with reduced neurotoxicity |
BR0314541A (pt) * | 2002-10-08 | 2005-07-26 | Allergan Inc | Tratamento de demência e doença de parkinson |
CA2501347A1 (en) * | 2002-10-08 | 2004-04-22 | Allergan, Inc. | Methods for the treatment of neurodegeneration |
US8410102B2 (en) | 2003-05-27 | 2013-04-02 | Galderma Laboratories Inc. | Methods and compositions for treating or preventing erythema |
US7439241B2 (en) | 2003-05-27 | 2008-10-21 | Galderma Laboratories, Inc. | Compounds, formulations, and methods for treating or preventing rosacea |
US20050020600A1 (en) | 2003-07-23 | 2005-01-27 | Scherer Warren J. | Methods of treating cutaneous flushing using selective alpha-2-adrenergic receptor agonists |
US8425929B2 (en) * | 2004-04-30 | 2013-04-23 | Allergan, Inc. | Sustained release intraocular implants and methods for preventing retinal dysfunction |
US20050244463A1 (en) | 2004-04-30 | 2005-11-03 | Allergan, Inc. | Sustained release intraocular implants and methods for treating ocular vasculopathies |
US8529927B2 (en) * | 2004-04-30 | 2013-09-10 | Allergan, Inc. | Alpha-2 agonist polymeric drug delivery systems |
DK1761266T3 (da) | 2004-05-25 | 2013-08-05 | Galderma Pharma Sa | Forbindelser, formuleringer og fremgangsmåder til at behandle eller forebygge inflammatoriske hudsygdomme |
US7931909B2 (en) * | 2005-05-10 | 2011-04-26 | Allergan, Inc. | Ocular therapy using alpha-2 adrenergic receptor compounds having enhanced anterior clearance rates |
ES2361932T3 (es) * | 2005-05-17 | 2011-06-24 | Santen Pharmaceutical Co., Ltd. | Inhibidor de angiogénesis que contiene un derivado de amina como ingrediente activo. |
US7592330B2 (en) * | 2005-08-08 | 2009-09-22 | Massachusetts Eye And Ear Infirmary | Methods and compositions for preserving the viability of photoreceptor cells |
US7534795B2 (en) * | 2005-10-25 | 2009-05-19 | Allergan, Inc. | Compounds and their use related to compositions for treating disease |
AU2006311577B2 (en) | 2005-11-09 | 2013-02-07 | Zalicus Inc. | Methods, compositions, and kits for the treatment of medical conditions |
US7850431B2 (en) * | 2005-12-02 | 2010-12-14 | Entegris, Inc. | System and method for control of fluid pressure |
US8506515B2 (en) | 2006-11-10 | 2013-08-13 | Glaukos Corporation | Uveoscleral shunt and methods for implanting same |
US8969415B2 (en) | 2006-12-01 | 2015-03-03 | Allergan, Inc. | Intraocular drug delivery systems |
US20080293728A1 (en) * | 2007-05-18 | 2008-11-27 | Mcintire Gregory L | Complexes Comprising alpha2-Adrenergic Receptor Agonists and Compositions |
WO2009003193A1 (en) * | 2007-06-27 | 2008-12-31 | Brooks Automation, Inc. | Position feedback for self bearing motor |
US9752615B2 (en) * | 2007-06-27 | 2017-09-05 | Brooks Automation, Inc. | Reduced-complexity self-bearing brushless DC motor |
US8283813B2 (en) * | 2007-06-27 | 2012-10-09 | Brooks Automation, Inc. | Robot drive with magnetic spindle bearings |
CA2709199A1 (en) | 2007-12-21 | 2009-07-02 | Galderma Laboratories, Inc. | Pre-surgical treatment |
US20090291073A1 (en) * | 2008-05-20 | 2009-11-26 | Ward Keith W | Compositions Comprising PKC-theta and Methods for Treating or Controlling Ophthalmic Disorders Using Same |
US8952011B2 (en) | 2008-08-01 | 2015-02-10 | Eye Therapies Llc | Compositions and methods for the treatment of nasal conditions |
US20100029662A1 (en) | 2008-08-01 | 2010-02-04 | Alpha Synergy Development, Inc. | Vasoconstriction compositions and methods of use |
US20100203165A1 (en) * | 2008-08-01 | 2010-08-12 | Gerald Horn | Compositions and methods for treatment of disorders or conditions of the eye |
US9095506B2 (en) | 2008-11-17 | 2015-08-04 | Allergan, Inc. | Biodegradable alpha-2 agonist polymeric implants and therapeutic uses thereof |
US8034813B2 (en) | 2008-11-18 | 2011-10-11 | Bausch & Lomb Incorporated | Polymorphs of brimonidine pamoate |
US10206813B2 (en) | 2009-05-18 | 2019-02-19 | Dose Medical Corporation | Implants with controlled drug delivery features and methods of using same |
US20100298335A1 (en) * | 2009-05-22 | 2010-11-25 | Kaufman Herbert E | Preparations and Methods for Ameliorating or Reducing Presbyopia |
US8299079B2 (en) | 2009-05-22 | 2012-10-30 | Kaufman Herbert E | Preparations and methods for ameliorating or reducing presbyopia |
US8987270B2 (en) | 2009-07-27 | 2015-03-24 | Eye Therapies Llc | Formulations of selective alpha-2 agonists and methods of use thereof |
MX361709B (es) | 2009-11-09 | 2018-12-07 | Allergan Inc | Composiciones y metodos para estimular el crecimiento del cabello. |
NZ599899A (en) | 2009-11-10 | 2014-10-31 | Allegro Pharmaceuticals Inc | Compositions and methods for inhibiting cellular adhesion or directing diagnostic or therapeutic agents to rgd binding sites |
US11673914B2 (en) | 2009-11-10 | 2023-06-13 | Allegro Pharmaceuticals, LLC | Peptide therapies for reduction of macular thickening |
EP2329849B1 (en) | 2009-11-18 | 2015-04-29 | Galderma Research & Development | Combination of alpha-2 adrenergic receptor agonist and non-steroidal anti-inflammatory agent for treating or preventing an inflammatory skin disorder |
US8394800B2 (en) * | 2009-11-19 | 2013-03-12 | Galderma Laboratories, L.P. | Method for treating psoriasis |
CA2782872A1 (en) * | 2009-12-17 | 2011-06-23 | Alpha Synergy Development, Inc. | Compositions and methods for ophthalmic delivery of nasal decongestants |
US9522153B2 (en) | 2009-12-22 | 2016-12-20 | Allergan, Inc. | Compositions and methods for lowering intraocular pressure |
EP2552448B1 (en) | 2010-03-26 | 2019-04-24 | Galderma Research & Development | Improved compositions comprising brimonidine for safe and effective treatment of telangiectasia |
US8513247B2 (en) | 2010-03-26 | 2013-08-20 | Galderma Laboratories, L.P. | Methods and compositions for safe and effective treatment of erythema |
US9554988B2 (en) | 2010-06-30 | 2017-01-31 | Galderma Research & Development | Method for preventing or treating skin tumor |
ES2585847T3 (es) | 2010-06-30 | 2016-10-10 | Galderma Research & Development | Utilización de un agonista del receptor adrenérgico alfa para prevenir o tratar un tumor de la piel |
US8053427B1 (en) | 2010-10-21 | 2011-11-08 | Galderma R&D SNC | Brimonidine gel composition |
SG189896A1 (en) | 2010-10-21 | 2013-06-28 | Galderma Sa | Brimonidine gel compositions and methods of use |
US8445526B2 (en) | 2011-02-03 | 2013-05-21 | Glaucoma & Nasal Therapies Llc | Compositions and methods for treatment of glaucoma |
EP2755549A1 (en) | 2011-09-13 | 2014-07-23 | Dose Medical Corporation | Intraocular physiological sensor |
CN103889417A (zh) | 2011-10-19 | 2014-06-25 | 高德美国际公司 | 减少与全身使用5型磷酸二脂酶抑制剂有关的面部潮红的方法 |
WO2013057580A1 (en) | 2011-10-19 | 2013-04-25 | Galderma Pharma S.A. | Method for treating capillary hemangiomas |
JP6511401B2 (ja) | 2013-02-15 | 2019-05-15 | アラーガン、インコーポレイテッドAllergan,Incorporated | 持続型薬物送達インプラント |
US9730638B2 (en) | 2013-03-13 | 2017-08-15 | Glaukos Corporation | Intraocular physiological sensor |
US8999938B2 (en) | 2013-06-21 | 2015-04-07 | Gnt Llc | Ophthalmic lipophilic drug delivery vehicle formulations |
JP6453318B2 (ja) | 2013-09-26 | 2019-01-16 | ガルデルマ ソシエテ アノニム | 委縮性皮膚瘢痕を治療するためのプロスタグランジンF2α及びその類似体 |
WO2018136669A2 (en) * | 2017-01-19 | 2018-07-26 | Allegro Phamaceuticals, Inc. | Therapeutic and neuroprotective peptides |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4029792A (en) | 1972-02-29 | 1977-06-14 | Pfizer Inc. | (2-Imidazolin-2-ylamino) substituted -quinoxalines and -quinazolines as antihypertensive agents |
BE795970A (fr) | 1972-02-29 | 1973-08-27 | Pfizer | Nouveaux derives de quinoleine, quinoxaline et quinazoline er composition pharmaceutiques les contenant |
US5180721A (en) | 1989-05-22 | 1993-01-19 | Allergan, Inc. | Combinations of selective alpha-adrenergic agonists and antagonists useful in lowering intraocular pressure |
US5077292A (en) | 1989-10-12 | 1991-12-31 | Allergan, Inc. | (2-imidazolin-2-ylamino) tetrahydroquinoxalines and methods for using same |
US5021416A (en) * | 1989-10-31 | 1991-06-04 | Allergan, Inc. | Method for using (2-imidazolin-2-ylamino) quinoxalines to reduce or maintain intraocular pressure |
US5215991A (en) | 1990-01-26 | 1993-06-01 | Allergan, Inc. | Combination of selective alpha-adrenergic agonists and Na+ /H+ ex |
CN1137755A (zh) | 1993-12-17 | 1996-12-11 | 普罗克特和甘保尔公司 | 用作α-2肾上腺素能受体兴奋剂的6-(2-咪唑啉基氨基)喹喔啉化合物 |
WO1996013267A2 (en) | 1994-10-27 | 1996-05-09 | Allergan | Combinations of prostaglandins and brimonidine or derivatives thereof for the treatment of glaucoma |
US5856329A (en) * | 1995-06-28 | 1999-01-05 | Allergan | Method of using (2-imidazolin-2-ylamino) quinoxalines in treating ocular neural injury |
AU4726597A (en) * | 1996-10-31 | 1998-05-22 | Nippon Shinyaku Co. Ltd. | Cranial nerve cell protectives |
-
1999
- 1999-01-04 US US09/225,036 patent/US6194415B1/en not_active Expired - Lifetime
-
2000
- 2000-01-04 CN CNB008025266A patent/CN1205932C/zh not_active Expired - Lifetime
- 2000-01-04 BR BR0007394-6A patent/BR0007394A/pt not_active Application Discontinuation
- 2000-01-04 EP EP00906868A patent/EP1146877B1/en not_active Expired - Lifetime
- 2000-01-04 ES ES00906868T patent/ES2251968T3/es not_active Expired - Lifetime
- 2000-01-04 AT AT00906868T patent/ATE311187T1/de active
- 2000-01-04 CA CA002357014A patent/CA2357014C/en not_active Expired - Lifetime
- 2000-01-04 WO PCT/US2000/000068 patent/WO2000040245A1/en active IP Right Grant
- 2000-01-04 DE DE60024407T patent/DE60024407T2/de not_active Expired - Lifetime
- 2000-01-04 AU AU28460/00A patent/AU762641B2/en not_active Expired
- 2000-01-04 JP JP2000592002A patent/JP2002534387A/ja active Pending
- 2000-09-06 US US09/655,579 patent/US6248741B1/en not_active Expired - Fee Related
-
2001
- 2001-06-18 US US09/883,753 patent/US20010046998A1/en not_active Abandoned
-
2002
- 2002-02-22 US US10/080,451 patent/US6465464B2/en not_active Expired - Lifetime
- 2002-04-18 HK HK02102938.9A patent/HK1040938B/zh not_active IP Right Cessation
- 2002-06-03 US US10/162,088 patent/US20020183328A1/en not_active Abandoned
-
2005
- 2005-12-07 US US11/296,116 patent/US8455492B2/en not_active Expired - Lifetime
-
2007
- 2007-06-27 JP JP2007168778A patent/JP2007291129A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
EP1146877B1 (en) | 2005-11-30 |
US6194415B1 (en) | 2001-02-27 |
AU762641B2 (en) | 2003-07-03 |
CN1205932C (zh) | 2005-06-15 |
DE60024407D1 (de) | 2006-01-05 |
CA2357014C (en) | 2009-08-04 |
US20010046998A1 (en) | 2001-11-29 |
HK1040938B (zh) | 2006-05-12 |
US20020111357A1 (en) | 2002-08-15 |
JP2007291129A (ja) | 2007-11-08 |
ATE311187T1 (de) | 2005-12-15 |
JP2002534387A (ja) | 2002-10-15 |
US8455492B2 (en) | 2013-06-04 |
WO2000040245A1 (en) | 2000-07-13 |
US6465464B2 (en) | 2002-10-15 |
CN1335773A (zh) | 2002-02-13 |
DE60024407T2 (de) | 2006-08-10 |
CA2357014A1 (en) | 2000-07-13 |
US6248741B1 (en) | 2001-06-19 |
EP1146877A1 (en) | 2001-10-24 |
AU2846000A (en) | 2000-07-24 |
US20020183328A1 (en) | 2002-12-05 |
HK1040938A1 (en) | 2002-06-28 |
ES2251968T3 (es) | 2006-05-16 |
US20060089361A1 (en) | 2006-04-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR0007394A (pt) | Método de usar quinoxalinas de(2-imidazolin-2-ilamino) no tratamento de lesãonervosa | |
DE69636012D1 (de) | Verwendung von (2-imidazolin-2-yl-amino)quinoxalinen zur behandlung von augennerfverletzung | |
AR016415A1 (es) | Uso de un compuesto derivado de la quinazolina para la fabricacion de un medicamento util para tratar o inhibir polipos colonicos | |
AU2003301020A8 (en) | Isoquinolinone derivatives and their use as therapeutic agents | |
AR012660A1 (es) | Uso de compuestos de quinazolina para la manufactura de un medicamento util para el tratamiento de enfermedades poliquisticas del rinon. | |
WO2004018419B1 (en) | Benzimidazole quinolinones and uses thereof | |
BR9604974A (pt) | Composição farmacêutica contendo benzimidazol para inibir o crescimento de canceres | |
DE60027435D1 (de) | Substituierte 2-arylbenzazole und ihre verwendung als antitumorale mittel | |
ES2105617T3 (es) | Derivados de piperacina como antagonistas de 5-ht. | |
NO963706L (no) | Benzenkondenserte heterosykliske derivater og deres anvendelse | |
KR880009948A (ko) | 항 알레르기 및 항 염증제로서 용도를 갖는 신규의 나프탈렌 유도체 | |
DE69922009D1 (de) | Imidazolverbindungen und ihre verwendung als adenosindeaminase-inhibitoren | |
KR950703339A (ko) | 질소 치환된 아크리딘의 대사를 억제하기 위한 시토크롬 P450 억제제의 용도(Use of Cytochrome P450 Inhibitors for Inhibiting he Metabolism of Nitrogen Substituted Acridine) | |
KR960703912A (ko) | 중추신경계 활성을 갖는 헤테로사이클 아민(heterocyclic amines having central nervous system activity) | |
AR021838A1 (es) | Nuevos bis-benzimidazoles | |
ATE279925T1 (de) | Verwendung von halofuginon zur herstellung eines medikaments zur vorbeugung von neovaskularisation und zur behandlung bösartiger tumore | |
ATE251164T1 (de) | Substituierte benzimidazole, ihre herstellung und ihre verwendung als mittel gegen parasitäre protozoen | |
PT1068199E (pt) | N-ariloxietil-indoli-alquilaminas para o tratamento da depressao | |
PT1075476E (pt) | Novos benzimidazoles e benzoxazoles | |
WO2001040187A3 (en) | Compound having effect of promoting neuron differentiation | |
ECSP993163A (es) | Nuevos bis - benzimidazoles |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B25A | Requested transfer of rights approved |
Free format text: ALLERGAN SALES, LLC (US) |
|
B25A | Requested transfer of rights approved |
Free format text: ALLERGAN, INC (US) |
|
B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
B09B | Patent application refused [chapter 9.2 patent gazette] |
Free format text: INDEFIRO O PEDIDO DE ACORDO COM O(S) ARTIGO(S) 10 ( VIII ) DA LPI |
|
B12B | Appeal against refusal [chapter 12.2 patent gazette] |